Global CRO footprint ARIANNE operates clinical trials across North America, Europe, Australia and expanding economies in Asia, South America and Africa, signaling opportunities to support globalized study execution and regulatory submissions in multiple regions.

Regulatory excellence With dedicated regulatory personnel in key countries and emphasis on FDA and ICH guidelines, there is potential to upsell end-to-end regulatory affairs services, submissions optimization, and accelerated health authority interactions.

Phased trial expertise Capabilities span from Phase I to IV, offering a one-stop CRO for early to late-stage programs, which aligns with sponsors seeking unified operations, faster timelines, and consistent quality across phases.

Cost and enrollment leverage Access to rapid patient recruitment and cost-effective sites in diverse regions presents an opportunity to position ARIANNE as a strategic partner for trials requiring fast enrollments and budget-conscious execution.

Small to mid-size focus With 51-200 employees and revenue in the small to mid-market range, ARIANNE can be a compelling partner for mid-sized biotech and pharmaceutical companies seeking personalized CRO services with flexible scalability.